Payment overview · 2025
General Payments
$18.85
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Agey, DO
Allopathic & Osteopathic Physicians|Family Medicine · NORWALK, IA · NPI 1013926807
Verified facts
What the public records show
CMS Open Payments records show Michael Agey, DO received $18.85 in general payments during 2025 across 1 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 96 |
| Omeprazole | Omeprazole | 386 | 101 |
| Lisinopril | Lisinopril | 341 | 91 |
| Losartan Potassium | Losartan Potassium | 300 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 73 |
| Gabapentin | Gabapentin | 233 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 55 |
| Simvastatin | Simvastatin | 171 | 45 |
| Eliquis | Apixaban | 162 | 32 |
| Metformin Hcl Er | Metformin Hcl | 156 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 29 |
| Furosemide | Furosemide | 142 | 46 |
| Metformin Hcl | Metformin Hcl | 134 | 35 |
| Benazepril Hcl | Benazepril Hcl | 121 | 30 |
| Allopurinol | Allopurinol | 102 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 24 |
| Sertraline Hcl | Sertraline Hcl | 77 | 23 |
| Warfarin Sodium | Warfarin Sodium | 74 | 12 |
| Meloxicam | Meloxicam | 64 | 19 |
| Alendronate Sodium | Alendronate Sodium | 58 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | 17 |
| Carvedilol | Carvedilol | 57 | 20 |
| Tramadol Hcl | Tramadol Hcl | 55 | 17 |
| Atenolol | Atenolol | 54 | 12 |
| Finasteride | Finasteride | 54 | 18 |
| Trazodone Hcl | Trazodone Hcl | 54 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Lovastatin | Lovastatin | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Spironolactone | Spironolactone | 48 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 13 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Alprazolam | Alprazolam | 44 | 14 |
| Amoxicillin | Amoxicillin | 43 | 31 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Baclofen | Baclofen | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Prednisone | Prednisone | 41 | 26 |
| Valacyclovir | Valacyclovir Hcl | 40 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Glimepiride | Glimepiride | 38 | 11 |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Nystatin | Nystatin | 33 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Famotidine | Famotidine | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Mesalamine Er | Mesalamine | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Etodolac | Etodolac | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.85 · 1 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error